Drugs / ALEPLASININ
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00739037 | Aug → Dec 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00684710 | Apr → Aug 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00663065 | Apr → Dec 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALEPLASININ | ChEMBL registry synonym — accepted as the source's own label CHEMBL325424 ↗ |
| Known as | Aleplasinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL325424 ↗ |
| Known as | Aleplasinine | ChEMBL registry synonym — accepted as the source's own label CHEMBL325424 ↗ |
| Known as | PAZ-417 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00663065 ↗ |
| Action | Inhibit | “Plasminogen activator inhibitor-1 inhibitor” CHEMBL325424 ↗ |
| Modality | Small molecule | — CHEMBL325424 ↗ |
| Route | Oral | “PAZ-417 Administered Orally” NCT00663065 ↗ |
| Target | SERPINE1 | “Plasminogen activator inhibitor-1 inhibitor” CHEMBL325424 ↗ |